Abstract

Lung cancer is the second most commonly diagnosed carcinoma and is the leading cause of cancer death. Although significant progress has been made towards its understanding and treatment, unraveling the complexities of lung cancer is still hampered by a lack of comprehensive knowledge on the mechanisms underlying the disease. High-throughput and multidimensional genomic data have shed new light on cancer biology. In this study, we developed a network-based approach integrating somatic mutations, the transcriptome, DNA methylation, and protein-DNA interactions to reveal the key regulators in lung adenocarcinoma (LUAD). By combining Bayesian network analysis with tissue-specific transcription factor (TF) and targeted gene interactions, we inferred 15 disease-related core regulatory networks in co-expression gene modules associated with LUAD. Through target gene set enrichment analysis, we identified a set of key TFs, including known cancer genes that potentially regulate the disease networks. These TFs were significantly enriched in multiple cancer-related pathways. Specifically, our results suggest that hepatitis viruses may contribute to lung carcinogenesis, highlighting the need for further investigations into the roles that viruses play in treating lung cancer. Additionally, 13 putative regulatory long non-coding RNAs (lncRNAs), including three that are known to be associated with lung cancer, and nine novel lncRNAs were revealed by our study. These lncRNAs and their target genes exhibited high interaction potentials and demonstrated significant expression correlations between normal lung and LUAD tissues. We further extended our study to include 16 solid-tissue tumor types and determined that the majority of these lncRNAs have putative regulatory roles in multiple cancers, with a few showing lung-cancer specific regulations. Our study provides a comprehensive investigation of transcription factor and lncRNA regulation in the context of LUAD regulatory networks and yields new insights into the regulatory mechanisms underlying LUAD. The novel key regulatory elements discovered by our research offer new targets for rational drug design and accompanying therapeutic strategies.

Highlights

  • Lung cancer is one of the leading causes of morbidity and mortality worldwide, especially in men and smokers

  • We focused on the identification of key regulatory elements, including transcription factor (TF) and long non-coding RNAs (lncRNAs), responsible for lung adenocarcinoma (LUAD) progression

  • RNA sequencing (RNA-seq) data generated from 56 normal and 484 lung adenocarcinoma tissue samples were obtained from the TCGA project

Read more

Summary

Introduction

Lung cancer is one of the leading causes of morbidity and mortality worldwide, especially in men and smokers. Genes 2018, 9, 12 are from lung cancer [1]. It has been estimated that there will be approximately 222,500 new lung cancer cases and 155,870 lung cancer-related deaths in the United States in 2017. Lung adenocarcinoma is a major subtype of non-small cell lung cancer that accounts for 85% of lung cancer cases. The initiation and progression of lung cancer is a complex process due to a number of factors, including environmental exposure [2], smoking [3,4], signaling pathways, as well as genomic variance. Long non-coding RNAs (lncRNAs) have been discovered to play critical roles in the development of various types of cancers [9,10,11,12,13]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.